Advertisement
UK markets close in 1 hour 27 minutes
  • FTSE 100

    7,853.90
    -23.15 (-0.29%)
     
  • FTSE 250

    19,337.49
    -113.18 (-0.58%)
     
  • AIM

    743.88
    -1.41 (-0.19%)
     
  • GBP/EUR

    1.1681
    -0.0002 (-0.02%)
     
  • GBP/USD

    1.2459
    +0.0020 (+0.16%)
     
  • Bitcoin GBP

    52,128.27
    +1,722.09 (+3.42%)
     
  • CMC Crypto 200

    1,384.34
    +71.71 (+5.78%)
     
  • S&P 500

    5,010.64
    -0.48 (-0.01%)
     
  • DOW

    37,938.00
    +162.62 (+0.43%)
     
  • CRUDE OIL

    82.67
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,396.90
    -1.10 (-0.05%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,762.55
    -74.85 (-0.42%)
     
  • CAC 40

    8,025.09
    +1.83 (+0.02%)
     

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth Biocare ASA
Hofseth Biocare ASA

Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at a price of NOK 2.69 per share.

Please see the attached notification form for further information.

Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Attachment